Sustained virological response in HCV patients treated with daclatasvir plus sofosbuvir, with or without ribavirin: a multicenter, field-practice experience

被引：0

作者：

Sacco, R. ^{[1
]}

Salomoni, E. ^{[2
]}

Parodi, S. ^{[1
]}

Gianni, E. ^{[3
]}

Gragnani, L. ^{[3
]}

Andreotti, G. ^{[4
]}

Brunetto, M. R. ^{[5
]}

Zignego, A. L. ^{[3
]}

Gattai, R. ^{[5
]}

Vivaldi, I. ^{[6
]}

De Luca, A. ^{[7
]}

Bartolozzi, D. ^{[2
]}

Cinelli, R. ^{[6
]}

Pozzi, M. ^{[2
]}

Coco, B. ^{[5
]}

Tapete, G. ^{[1
]}

Forte, P. ^{[8
]}

Puntili, R. ^{[8
]}

Ricciardi, L. ^{[9
]}

Sani, S. ^{[6
]}

Luchi, S. ^{[9
]}

Valoriani, B. ^{[7
]}

Riccardi, M. P. ^{[4
]}

Nencioni, C. ^{[4
]}

Aquilini, D. ^{[10
]}

Nerli, A. ^{[10
]}

Esperti, F. ^{[11
]}

Mazzotta, F. ^{[11
]}

Bresci, G. ^{[1
]}

Colombatto, P. ^{[5
]}

机构：

[1] Azienda Osped Univ Pisana, UO Gastroenterol & Malattie Ricambio, Pisa, Italy

[2] AOU Careggi, Malattie Infett & Trop, Florence, Italy

[3] AOU Careggi, Ctr MASVE Med Sperimentale & Clin, Florence, Italy

[4] Osped Misericordia, Malattie Infett, Grosseto, Italy

[5] Azienda Osped Univ Pisana, UO Epatol, Pisa, Italy

[6] Spedali Riuniti Livorno, Malattie Infett, Livorno, Italy

[7] Azienda Osped Univ Senese, Malattie Infett, Siena, Italy

[8] AOU Careggi, Gastroenterol 2, Florence, Italy

[9] Osped San Luca, Malattie Infett & Epatol, Lucca, Italy

[10] Nuovo Osped Prato, Malattie Infett, Prato, Italy

[11] Osped S Jacopo, Malattie Infett, Pistoia, Italy

来源：

JOURNAL OF HEPATOLOGY | 2017年 / 66卷 / 01期

关键词：

D O I：

10.1016/S0168-8278(17)31958-X

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

SAT-264

引用

页码：S734 / S734

页数：1

共 50 条

[41] DACLATASVIR PLUS SOFOSBUVIR WITH OR WITHOUT RIBAVIRIN FOR THE TREATMENT OF CHRONIC HCV INFECTION IN PATIENTS WITH DECOMPENSATED CIRRHOSIS: RESULTS OF A EUROPEAN MULTICENTRE COMPASSIONATE USE PROGRAM
Petersen, J.
Welzel, T.
Herzer, K.
Ferenci, P.
Gschwantler, M.
Cornberg, M.
Ingiliz, P.
Berg, T.
Spengler, U.
Weiland, O.
van der Valk, M.
Klinker, H.
Rockstroh, J.
Peck-Radosavljevic, M.
Zhao, Y.
Jimenez-Exposito, M. J.
Zeuzem, S.
JOURNAL OF HEPATOLOGY, 2016, 64 : S781 - S782
[42] Increasing ribavirin doses improves the sustained virological response in HCV patients not responding to pegylated interferon and ribavirin
Conti, F.
Lorenzini, S.
Riili, A.
Cursaro, C.
Scuteri, A.
Loggi, E.
Bernardi, M.
Andreone, P.
DIGESTIVE AND LIVER DISEASE, 2011, 43 : S92 - S92
[43] Treatment Failure With Daclatasvir Plus Sofosbuvir With or Without Ribavirin in Treatment Naive Patients With Chronic Hepatitis C Without Cirrhosis
Afzal, Muhammad
Tarar, Shahida Husain
Shah, Syed Muhammad Ali
Butt, Zamir
Ajmal, Muhammad
Younis, Irfan
Talat, Syed Usama
Akhtar, Hina
Ali, Javeria
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S560 - S561
[44] The effect of genetic variations on ribavirin pharmacokinetics and treatment response in HCV-4 Egyptian patients receiving sofosbuvir/daclatasvir and ribavirin
Abdelkawy, K. S.
El-Haggar, S. M.
Ziada, D. H.
Ebaid, N. F.
El-Magd, M. A.
Elbarbry, F. A.
BIOMEDICINE & PHARMACOTHERAPY, 2020, 121
[45] Daclatasvir plus Sofosbuvir with or without ribavirin in patients with chronic Hepatitis C genotype 3a in Pakistani population - A real world experience
Butt, Zamir
Shah, Syed Muhammad Ali
PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2019, 35 (02) : 409 - 413
[46] Peginterferon Plus Ribavirin and Sustained Virological Response in HCV-Related Cirrhosis: Outcomes and Factors Predicting Response
Fernandez-Rodriguez, Conrado M.
Alonso, Sonia
Martinez, Stella M.
Forns, Xavier
Sanchez-Tapias, Jose M.
Rincon, Diego
Rodriguez-Caravaca, Gil
Barcena, Rafael
Serra, Miguel A.
Romero-Gomez, Manuel
Fernandez, Inmaculada
Garcia-Samaniego, Javier
Fuente, Javier
Sola, Ricard
Moreno-Otero, Ricardo
Planas, Ramon
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 (10): : 2164 - 2172
[47] High virological efficacy of sofosbuvir/daclatasvir plus flat dose ribavirin in genotype 3 cirrhotic patients: a real life study
Giannelli, Valerio
Messina, Vincenzo
palitti, valerio pace
Vignally, Pascal
tarquini, pierluigi
Izzi, Antonio
Marignani, Massimo
Pompili, Maurizio
Ettorre, Giuseppe M.
Pellicelli, Adriano M.
HEPATOLOGY, 2017, 66 : 816A - 816A
[48] Sustained virologic response with daclatasvir plus sofosbuvir ± ribavirin (RBV) in chronic HCV genotype (GT) 1-infected patients who previously failed telaprevir (TVR) or boceprevir (BOC)
Sulkowski, M. S.
Gardiner, D. F.
Rodriguez-Torres, M.
Reddy, K. R.
Hassanein, T.
Jacobson, I.
Lawitz, E.
Lok, A. S.
Hinestrosa, F.
Thuluvath, P. J.
Schwartz, H.
Nelson, D. R.
Everson, G. T.
Eley, T.
Wind-Rotolo, M.
Huang, S. P.
Gao, M.
Mcphee, F.
Hernandez, D.
Sherman, D.
Hindes, R.
Symonds, W.
Pasquinelli, C.
Grasela, D. M.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 : 155 - 155
[49] SUSTAINED VIROLOGIC RESPONSE WITH DACLATASVIR PLUS SOFOSBUVIR ± RIBAVIRIN (RBV) IN CHRONIC HCV GENOTYPE (GT) 1-INFECTED PATIENTS WHO PREVIOUSLY FAILED TELAPREVIR (TVR) OR BOCEPREVIR (BOC)
Sulkowski, M. S.
Gardiner, D. F.
Rodriguez-Torres, M.
Reddy, K. R.
Hassanein, T.
Jacobson, I.
Lawitz, E.
Lok, A. S.
Hinestrosa, F.
Thuluvath, P. J.
Schwartz, H.
Nelson, D. R.
Everson, G. T.
Eley, T.
Wind-Rotolo, M.
Huang, S. -P.
Gao, M.
McPhee, F.
Hernandez, D.
Sherman, D.
Hindes, R.
Symonds, W.
Pasquinelli, C.
Grasela, D. M.
JOURNAL OF HEPATOLOGY, 2013, 58 : S570 - S570
[50] Daclatasvir exposure does not explain lower sustained virologic response rates in cirrhotic patients with HCV genotype 3 following 12 weeks of daclatasvir plus sofosbuvir treatment
Eley, Timothy
Wang, Reena
Huang, Shu-Pang
Gandhi, Yash
Cirincione, Brenda
LaCreta, Frank
Garimella, Tushar
HEPATOLOGY, 2015, 62 : 567A - 568A

← 1 2 3 4 5 →